Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CD59

CD59

Basics

Aliases:
This biomarker is also known as:
  • MEM43 antigen,
  • CD59 glycoprotein,
  • MIN3,
  • MAC-IP,
  • MIN2,
  • MSK21,
  • G344,
  • 1F5 antigen,
  • p18-20,
  • MACIF,
  • HRF-20,
  • EJ30,
  • MIRL,
  • CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344),
  • CD59 antigen, complement regulatory protein,
  • 20 kDa homologous restriction factor,
  • EJ16,
  • 16.3A5,
  • Membrane attack complex inhibition factor,
  • Membrane inhibitor of reactive lysis,
  • MAC-inhibitory protein,
  • EL32,
  • Protectin,
  • MIN1,
  • MIC11,

View in BioMuta

Description…

CD59 is an 18- to 25-kD glycoprotein expressed on all human peripheral blood leukocytes, erythrocytes, and several human cell lines. CD59 is a potent inhibitor of the complement membrane attack complex (MAC) action. It acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific and is involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.

Attributes

QA State: Under Review
Type: Protein
Short Name:
HGNC Name: CD59

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.